Moderna on Friday smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth, as some of its newer products gain momentum and Covid vaccine revenue outperforms.
Shares of Moderna rose roughly 3% in premarket trading on Friday.
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
"The new product and the diversification of geography is what has led to such a strong Q3," Moderna CEO Stéphane Bancel said in an interview ahead of the results.
The Moderna facility in Laval, Quebec, Canada, Sept. 19, 2025.
Graham Hughes | Bloomberg | Getty Images
For example, he said the company is seeing the "full-year impact" of its next-generation mRNA Covid vaccine, which won U.S. approval in May 2025.…